Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is the fifth leading cause of cancer deaths in the United States and the use of currently available combination chemotherapy has not been shown to definitely increase survival. Fourteen patients with histologically confirmed, unresectable or metastatic disease were treated with a combination of etoposide and 5-fluorouracil (5-FU). One patient had a complete response (CR), confirmed by second look laparotomy, that lasted for 30 months. No other responses were observed. While the long-lasting CR was encouraging, the overall response rate was no different from that reported with 5-FU alone.
Christiansen
N P
NP
Division of Medical Oncology, University of Minnesota Hospital and Clinic, Minneapolis 55455.
Kennedy
B J
BJ
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D005472:Fluorouracil